To identify strategies that can improve the effect of CD47 blockade, we next assessed whether TMZ, a DNA alkylating agent that is part of the standard of care treatment for GBM13, can increase pro-phagocytosis signals on GBM cells. This evidence concerns the gene CD47 and glioblastoma.